Fig. 6: Alemtuzumab ameliorates HDM-induced AHR in preventative and therapeutic humanized mice models. | Mucosal Immunology

Fig. 6: Alemtuzumab ameliorates HDM-induced AHR in preventative and therapeutic humanized mice models.

From: CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation

Fig. 6

a Total PBMCs from HDM-positive patients (5 million) were adoptively intravenously transferred into Rag2−/−Il2rg−/− mice that were sensitized on days 3 and 4 (n = 6 donors). At day 8, mice received an intraperitoneal injection of Alemtuzumab or control isotype (250 μg). Subsequently, the humanized mice were challenges with HDM (50 µg) or PBS i.n. on days 9, 10, and 11. Measurement of lung function and inflammation were performed on day 14. b Lung resistance measured in anesthetized, tracheostomized, and mechanically ventilated mice that were exposed to increasing concentrations of methacholine. c Number of eosinophils in BAL. d Five million total PBMCs from HDM-positive patients (n = 6 donors) were adoptively intravenously transferred into Rag2−/−Il2rg−/− mice that were then sensitized on days 3 and 4. The humanized mice were then challenges with HDM (50 µg) or PBS i.n. on days 9, 10, and 11. On day 12, mice received an intraperitoneal injection of Alemtuzumab or control isotype (250 μg). Measurement of lung function and inflammation were performed on day 14. e Lung resistance. f Number of eosinophils in BAL. Statistical analysis, two-tailed Student’s t-test. ***P < 0.001, and ****P < 0.0001. Human, mouse, and lung images are provided with permission from Servier Medical Art.

Back to article page